Zearalenone and its metabolites in urine and breast cancer risk: A case-control study in Tunisia
Zearalenone and its metabolites in urine and breast cancer risk: A case-control study in Tunisia
复制标题
DOI：
10.1016/j.chemosphere.2014.12.055
复制
发表时间：
2015-06-01
期刊：
影响因子：
8.8
通讯作者：
Hedili, A.
中科院分区：
文献类型：
--
作者：
Belhassen, H.;Jimenez-Diaz, I.;Hedili, A.
玉米赤霉烯酮（ZON）是一种由镰刀菌属真菌产生的非甾体类雌激素毒素。人类和动物的接触风险是食用受污染的食物和动物饲料。有报道称，ZON及其代谢产物可促进肿瘤的发生发展。本病例对照研究的目的是通过测量ZON及其5种代谢物（α-玉米赤霉烯醇[α-ZOL]、β-玉米赤霉烯醇[β-ZOL]、α-玉米赤霉醇[zeranol，α-ZAL]、β-玉米赤霉醇[teranol，β-zAL]和玉米赤霉酮[ZAN]）的尿液浓度来估计这些化合物的暴露量，并评估与此暴露量相关的乳腺癌风险。通过液-液萃取（LLE）和超高效液相色谱串联质谱检测（UHPLC-MS/MS）进行化学分析。进行了统计分析，以确定暴露于这些化合物和乳腺癌的发展之间的关联。通过非条件logistic回归计算粗比值比（OR）和调整后比值比（OR）及其95%置信区间（CI），以估计相关性的大小。结果（校正OR = 1.54，95%CI = 1.10-2.77）提示α-ZAL在乳腺癌发生中可能起作用。(C)2015爱思唯尔有限公司版权所有。
Zearalenone (ZON) is a non-steroidal estrogenic mycotoxin produced by Fusarium species. The exposure risk to humans and animals is the consumption of contaminated food and animal feeds. It has been reported that ZON and some of its metabolites promote the development of hormone-dependent tumors. The aim of this case-control study was to estimate exposure to ZON and its five metabolites (a-zearalenol [alpha-ZOL], beta-zearalenol [beta-ZOL], alpha-zearalanol [zeranol, alpha-ZAL], beta-zearalanol [teranol, beta-zAL] and zearalanone [ZAN]) by measuring urinary concentrations of these compounds, and to evaluate the risk of breast cancer related to this exposure. Chemical analyses were carried out by liquid-liquid extraction (LLE) and ultra-high performance liquid chromatography with tandem mass spectrometry detection (UHPLC-MS/MS). Statistical analyses were performed in order to determine the association between exposure to these compounds and the development of breast cancer. Crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were calculated by unconditional logistic regression to estimate the magnitude of the associations. The obtained results (adjusted OR = 1.54,95% CI = 1.10-2.77) suggest a potential role of alpha-ZAL in the risk of developing breast cancer. (C) 2015 Elsevier Ltd. All rights reserved.